TGTX Stock Analysis: Buy, Sell, or Hold?
TGTX - TG Therapeutics, Inc.
$46.47
-5.56 (-10.69%)
▼
5d:
-16.65%
30d:
-12.83%
90d:
+37.28%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 03, 2026
0d
Smart Money Accumulation
None View Scanner →
Strength: 7.9/10
Get Alerted When TGTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TGTX is down 16.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TGTX is down 16.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$100.95
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$62.68
25.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TGTX is currently trading at $46.47, which is considered oversold relative to its 30-day fair value range of $52.41 to $57.06. The stock's valuation (Forward PE: 15.9) is in line with its historical norms (15.8). At these levels, the market is pricing in 0.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TGTX is in a strong uptrend. The price is currently testing key support at $45.91. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $68.43 (+31.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TGTX is in a strong uptrend. The price is currently testing key support at $45.91. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 10.7% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $68.43 (+31.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$52.41 -
$57.06
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
75.7%
Protect Your Profits
Holding TGTX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-10.7%)
- BULLISH: Trading 31.5% below Wall St target ($68.43)
- NEUTRAL: Market pricing in 0.2% annual earnings growth - fairly valued
- WARNING: Recommendation downgraded due to -16.6% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$52.41 -
$57.06
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$45.91
Resistance Level
$57.58
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.86
Wall Street Target
$68.43
(+31.5%)
Revenue Growth (YoY)
69.6%
Earnings Growth (YoY)
300.0%
Profit Margin
66.0%
Valuation Premium vs History
+0.2% premium
PE vs Historical
15.9 vs 15.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.2%
(market-implied from PE analysis)
1-Year Target
$52.13
(+0%)
2-Year Target
$52.24
(+0%)
3-Year Target
$52.34
(+1%)
3-Yr Target (if PE normalizes)
(PE: 16→16)
PE COMPRESSION
$52.15
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.7, Growth: 108.7%)
$229.56
(+341%)
Base:
(SPY PE: 15.9, Growth: 108.7%)
$175.60
(+238%)
Bear:
(PE: 13.5, Growth: 108.7%)
$149.26
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (16x PE) as earnings recover.
Trailing PE: 18.72 | Current EPS (TTM): $2.86
Bull Case
$67.55
(+30%)
Analyst growth 14.7%, PE expands to 20.6
Base Case
$61.41
(+18%)
Market implied 14.7%, PE stable at 18.7
Bear Case
$36.40
(-30%)
Severe decline -20.0%, PE contracts to 15.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 03, 2026 2:01 PM ET
Data refreshes hourly during market hours. Next update: 3:01 PM
Data refreshes hourly during market hours. Next update: 3:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TGTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
Advanced TGTX Option Strategies
Professional options setups generated by AI based on today's TGTX price and gamma walls.
